Investigational drugs in Alzheimer's disease: current progress

PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

(2017) Noel G. Faux et al.   JOURNAL OF ALZHEIMERS DISEASE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease

(2013) Camryn Berk et al.   DRUGS & AGING

Deep brain stimulation in dementia-related disorders

(2013) Sarah Hescham et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Long-Term Treatment of Thalidomide Ameliorates Amyloid-Like Pathology through Inhibition of β-Secretase in a Mouse Model of Alzheimer’s Disease

(2013) Ping He et al.   PLoS One

Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy

(2013) Alireza Atri et al.   Alzheimers Research & Therapy

Increased Cerebral Metabolism After 1 Year of Deep Brain Stimulation in Alzheimer Disease

(2012) Gwenn S. Smith et al.   ARCHIVES OF NEUROLOGY

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study

(2012) B. Vellas et al.   Current Alzheimer Research

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

(2012) Bruno P Imbimbo et al.   Expert Review of Clinical Immunology

A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer disease

(2012) Rashid Deane et al.   JOURNAL OF CLINICAL INVESTIGATION

The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice

(2012) B. Zhang et al.   JOURNAL OF NEUROSCIENCE

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Alzheimer's disease market: hope deferred

(2012) Zelicia Gerald et al.   NATURE REVIEWS DRUG DISCOVERY

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment

(2011) Suzanne Craft   ARCHIVES OF NEUROLOGY

T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice

(2011) Tetsuo Fukushima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury

(2011) Sandra Magnoni et al.   BRAIN

Tau as a Therapeutic Target for Alzheimers Disease

(2011) A. Boutajangout et al.   Current Alzheimer Research

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

(2010) Marwan N. Sabbagh et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study

(2010) Taro Goto et al.   Alzheimers & Dementia

Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy

(2010) K. R. Brunden et al.   JOURNAL OF NEUROSCIENCE

RG3487, a Novel Nicotinic  7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents

(2010) T. L. Wallace et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

An update on treatment and prevention strategies for Alzheimer’s disease

(2009) Judith Neugroschl et al.   Current Neurology and Neuroscience Reports

Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers

(2009) Fernanda G. De Felice et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nicotinic receptor agonists and antagonists increase sAPPα secretion and decrease Aβ levels in vitro

(2008) M. Mousavi et al.   NEUROCHEMISTRY INTERNATIONAL

Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways

(2007) Hani Atamna et al.   FASEB JOURNAL